HIMS - June 24 Qullamaggie Breakout and Episodic PivotI believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months.
1) Their compounded GLP-1 is significantly cheaper
2) Their platform makes it easier and more accessible to purchase
3) It is lifestyle related so monthly recurring purchases is encouraged
4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing.
As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers
This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting
Source
@moizali - x.com
www.triplewhale.com